A systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone agonists (GnRHa) in women of child-bearing age with autoimmune rheumatic disease
- 3 March 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Clinical Immunology
- Vol. 16 (3), 321-333
- https://doi.org/10.1080/1744666X.2020.1724091
Abstract
Objectives: To systematically review risk of sustained amenorrhea with intravenous (IV) cyclophosphamide in autoimmune rheumatic disease (ARD), and evaluate efficacy of gonadotropin-releasing hormone agonists (GnRHa) to reduce this risk. Methods: Systematic search for papers reporting incidence of sustained amenorrhea >= 12 months in ARD following: IV cyclophosphamide; or GnRHa and IV cyclophosphamide compared to IV cyclophosphamide alone. Results: From 31 articles and 1388 patients (mean age 27.7 years) sustained amenorrhea occurred in 273 patients (19.7%). Of 56 patients (mean age range 23.9-25.6 years) receiving GnRHa and IV cyclophosphamide, and 37 controls (mean age range 25-30.1 years) given IV cyclophosphamide only, sustained amenorrhea occurred in 2/56 (3.6%) patients treated with GnRHa, compared to 15/37 (40.5%) controls. Pooled odds ratio of sustained amenorrhea with GnRHa and cyclophosphamide versus cyclophosphamide alone was 0.054 (95% CI 0.0115-0.2576 p < 0.001), corresponding to a number needed to treat of 2.7 (95% CI 1.955-4.388) and absolute risk reduction of 36.95% (95% CI 35.6-38.4%). Conclusion: Sustained amenorrhea with IV cyclophosphamide was observed in patients with ARD, especially with increasing age and cumulative doses >5 g. GnRHa reduced this risk and should be considered with IV cyclophosphamide in women of childbearing age with ARD.This publication has 52 references indexed in Scilit:
- Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patientsGynecological Endocrinology, 2012
- Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective studyArthritis Research & Therapy, 2010
- Menstrual and hormonal alterations in juvenile systemic lupus erythematosusLupus, 2009
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Fertility status among women treated for aggressive non-Hodgkin's lymphomaLeukemia & Lymphoma, 2006
- Maintenance Therapies for Proliferative Lupus Nephritis: Mycophenolate Mofetil, Azathioprine and Intravenous CyclophosphamideLupus, 2005
- MENSTRUAL DISORDERS IN GIRLS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH CYCLOPHOSPHAMIDERheumatology, 1995
- New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritisLupus, 1995
- Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosusLupus, 1995
- Therapy of Lupus NephritisThe New England Journal of Medicine, 1986